217 related articles for article (PubMed ID: 25615005)
21. Current and future roles of targeted therapy and immunotherapy in advanced melanoma.
Olszanski AJ
J Manag Care Spec Pharm; 2014 Apr; 20(4):346-56. PubMed ID: 24684639
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of dabrafenib and trametinib in combination as adjuvant treatment of BRAF V600E/K mutation-positive melanoma from a US healthcare payer perspective.
Gerbasi ME; Stellato D; Ghate SR; Ndife B; Moynahan A; Mishra D; Gunda P; Koruth R; Delea TE
J Med Econ; 2019 Dec; 22(12):1243-1252. PubMed ID: 31223037
[No Abstract] [Full Text] [Related]
23. Cost-Effectiveness Analysis of Dabrafenib Plus Trametinib and Vemurafenib as First-Line Treatment in Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma in China.
Gao T; Liu J; Wu J
Int J Environ Res Public Health; 2021 Jun; 18(12):. PubMed ID: 34201096
[No Abstract] [Full Text] [Related]
24. Patterns of use of systemic therapies among patients with metastatic melanoma: a retrospective claims database analysis in the United States.
Ma Q; Chen YJ; Hines DM; Munakata J; Batty N; Barber BL; Zhao Z
J Dermatolog Treat; 2017 Sep; 28(6):549-553. PubMed ID: 28100090
[TBL] [Abstract][Full Text] [Related]
25. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network.
Voskens CJ; Goldinger SM; Loquai C; Robert C; Kaehler KC; Berking C; Bergmann T; Bockmeyer CL; Eigentler T; Fluck M; Garbe C; Gutzmer R; Grabbe S; Hauschild A; Hein R; Hundorfean G; Justich A; Keller U; Klein C; Mateus C; Mohr P; Paetzold S; Satzger I; Schadendorf D; Schlaeppi M; Schuler G; Schuler-Thurner B; Trefzer U; Ulrich J; Vaubel J; von Moos R; Weder P; Wilhelm T; Göppner D; Dummer R; Heinzerling LM
PLoS One; 2013; 8(1):e53745. PubMed ID: 23341990
[TBL] [Abstract][Full Text] [Related]
26. Phase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-α in patients with metastatic melanoma.
Alrwas A; Papadopoulos NE; Cain S; Patel SP; Kim KB; Deburr TL; Bassett R; Hwu WJ; Bedikian AY; Davies MA; Woodman SE; Hwu P
Melanoma Res; 2014 Aug; 24(4):342-8. PubMed ID: 24743052
[TBL] [Abstract][Full Text] [Related]
27. Cost effectiveness of dabrafenib as a first-line treatment in patients with BRAF V600 mutation-positive unresectable or metastatic melanoma in Canada.
Delea TE; Amdahl J; Wang A; Amonkar MM; Thabane M
Pharmacoeconomics; 2015 Apr; 33(4):367-80. PubMed ID: 25488880
[TBL] [Abstract][Full Text] [Related]
28. Real-world incidence and burden of adverse events among non-metastatic prostate cancer patients treated with secondary hormonal therapies following androgen deprivation therapy.
Shah A; Shah R; Kebede N; Mohamed A; Botteman M; Waldeck R; Hussain A
J Med Econ; 2020 Apr; 23(4):330-346. PubMed ID: 31835965
[No Abstract] [Full Text] [Related]
29. Health Care Resource Utilization and Costs in First-Line Treatments for Patients with Metastatic Melanoma in the United States.
Klink AJ; Chmielowski B; Feinberg B; Ahsan S; Nero D; Liu FX
J Manag Care Spec Pharm; 2019 Aug; 25(8):869-877. PubMed ID: 30945965
[TBL] [Abstract][Full Text] [Related]
30. Acceptability of Drugs in the Treatment of Unresectable/Metastatic BRAF V600-Mutant Melanoma: A Systematic Review and Network Meta-Analysis.
Hong L; Huang P; Zheng X; Ye X; Zhao H; Wang J; Shao Y
Front Oncol; 2022; 12():865656. PubMed ID: 35530323
[TBL] [Abstract][Full Text] [Related]
31. Real-World Costs of Adverse Events in First-Line Treatment of Metastatic Non-Small Cell Lung Cancer.
Engel-Nitz NM; Johnson MP; Bunner SH; Ryan KJ
J Manag Care Spec Pharm; 2020 Jun; 26(6):729-740. PubMed ID: 32463768
[TBL] [Abstract][Full Text] [Related]
32. Neutropenia-related costs in patients treated with first-line chemotherapy for advanced non-small cell lung cancer.
Stokes ME; Muehlenbein CE; Marciniak MD; Faries DE; Motabar S; Gillespie TW; Lipscomb J; Knopf KB; Buesching DP
J Manag Care Pharm; 2009 Oct; 15(8):669-82. PubMed ID: 19803556
[TBL] [Abstract][Full Text] [Related]
33. Possible immune adverse events as predictors of durable response to BRAF inhibitors in patients with BRAF V600-mutant metastatic melanoma.
Ben-Betzalel G; Baruch EN; Boursi B; Steinberg-Silman Y; Asher N; Shapira-Frommer R; Schachter J; Markel G
Eur J Cancer; 2018 Sep; 101():229-235. PubMed ID: 30096703
[TBL] [Abstract][Full Text] [Related]
34. A cost-effectiveness analysis of trametinib plus dabrafenib as first-line therapy for metastatic BRAF V600-mutated melanoma in the Swiss setting.
Matter-Walstra K; Braun R; Kolb C; Ademi Z; Dummer R; Pestalozzi BC; Schwenkglenks M
Br J Dermatol; 2015 Dec; 173(6):1462-70. PubMed ID: 26332527
[TBL] [Abstract][Full Text] [Related]
35. Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma.
Daud A; Tsai K
Oncologist; 2017 Jul; 22(7):823-833. PubMed ID: 28526719
[TBL] [Abstract][Full Text] [Related]
36. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha.
Legha SS; Ring S; Bedikian A; Plager C; Eton O; Buzaid AC; Papadopoulos N
Ann Oncol; 1996 Oct; 7(8):827-35. PubMed ID: 8922197
[TBL] [Abstract][Full Text] [Related]
37. Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma.
Si L; Zhang X; Shin SJ; Fan Y; Lin CC; Kim TM; Dechaphunkul A; Maneechavakajorn J; Wong CS; Ilankumaran P; Lee DY; Gasal E; Li H; Guo J
Eur J Cancer; 2020 Aug; 135():31-38. PubMed ID: 32534242
[TBL] [Abstract][Full Text] [Related]
38. Adverse Event Management in Patients with
Chalmers A; Cannon L; Akerley W
Oncologist; 2019 Jul; 24(7):963-972. PubMed ID: 30598499
[TBL] [Abstract][Full Text] [Related]
39. Cost-Effectiveness of the Dabrafenib Schedule in Combination With Trametinib Compared With Other Targeted Therapies, Immunotherapy, and Dacarbazine for the Treatment of Unresectable or Metastatic Melanoma With BRAFV600 Mutation in Colombia.
Gil-Rojas Y; Lasalvia P; Hernández F; Castañeda-Cardona C; Castrillón-Correa J; Herrera D; Rosselli D
Value Health Reg Issues; 2021 Dec; 26():182-190. PubMed ID: 34673349
[TBL] [Abstract][Full Text] [Related]
40. Healthcare and economic burden of adverse events among patients with chronic myelogenous leukemia treated with BCR-ABL1 tyrosine kinase inhibitors.
Lin J; Makenbaeva D; Lingohr-Smith M; Bilmes R
J Med Econ; 2017 Jul; 20(7):687-691. PubMed ID: 28287043
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
